Show simple item record

AuthorSaid Suliman, Ammar
AuthorKhoder, Mouhamad
AuthorTolaymat, Ibrahim
AuthorWebster, Matt
AuthorAlany, Raid G.
AuthorWang, Weiguang
AuthorElhissi, Abdelbary
AuthorNajlah, Mohammad
Available date2023-02-28T10:10:25Z
Publication Date2021
Publication NamePharmaceutics
ResourceScopus
URIhttp://dx.doi.org/10.3390/pharmaceutics13010084
URIhttp://hdl.handle.net/10576/40529
AbstractDiethyldithiocarbamate Copper II (DDC-Cu) has shown potent anticancer activity against a wide range of cancer cells, but further investigations are hindered by its practical insolubility in water. In this study, inclusion complexes of DDC-Cu with hydroxypropyl beta-cyclodextrin (HP) or sulfobutyl ether beta-cyclodextrin (SBE) were prepared and investigated as an approach to enhance the apparent solubility of DDC-Cu. Formulations were prepared by simple mixing of DDC-Cu with both cyclodextrin (CDs) at room temperature. Phase solubility assessments of the resulting solutions were performed. DDC-Cu CD solutions were freeze-dried for further characterisations by DSC, thermogravimetric analysis (TGA) and FT-IR. Stability and cytotoxicity studies were also performed to investigate the maintenance of DDC-Cu anticancer activity. The phase solubility profile deviated positively from the linearity (Ap type) showing significant solubility enhancement of the DDC-Cu in both CD solutions (approximately 4 mg/mL at 20% w/w CD solutions). The DSC and TGA analysis confirmed the solid solution status of DDC-Cu in CD. The resulting solutions of DDC-Cu were stable for 28 days and conveyed the anticancer activity of DDC-Cu on chemoresistant triple negative breast cancer cell lines, with IC50 values less than 200 nM. Overall, cyclodextrin DDC-Cu complexes offer a great potential for anticancer applications, as evidenced by their very positive effects against chemoresistant triple negative breast cancer cells.
SponsorFunding: This research is funded by NPRP grant (NPRP9-337-3-069) from the Qatar National Funding: This research is funded by NPRP grant (NPRP9-337-3-069) from the Qatar National Re-Research Fund (a member of Qatar Foundation). The findings herein reflect the work, and are solely search Fund (a member of Qatar Foundation). The findings herein reflect the work, and are solely the responsibility, of the authors. the responsibility, of the authors.
Languageen
PublisherMDPI AG
SubjectBeta-cyclodextrin
Chemoresistance
Diethyldithiocarbamate copper II
Solubility
Triple negative breast cancer
TitleCyclodextrin diethyldithiocarbamate copper ii inclusion complexes: A promising chemotherapeutic delivery system against chemoresistant triple negative breast cancer cell lines
TypeArticle
Pagination12-Jan
Issue Number1
Volume Number13
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record